Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings.

Cécile PhilippoteauxValentine DeprezAurore NottezÉmeline CailliauEric HouvenagelXavier DeprezPeggy PhilippeTristan PascartRené-Marc FlipoVincent Goeb Jean-Guillaume Letarouilly

Published in: Journal of clinical medicine (2022)

Our study did not show a significant change in patients characteristics starting a JAKi after the EMA's warnings, probably due to a lack of power. Though, the lower proportion of VTE history in patients after May 2019 suggests that rheumatologists have taken into account the potential VTE risk. These results need to be confirmed by further evidence.

Keyphrases

end stage renal disease
venous thromboembolism
rheumatoid arthritis
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
systemic lupus erythematosus
climate change
ankylosing spondylitis
disease activity
idiopathic pulmonary fibrosis